

CellMosaic, Inc. 10A Roessler Road Woburn, MA 01801, USA Phone: 781-463-0002; Fax: 781-998-4694; E-mail: info@cellmosaic.com

Ciprofloxacin–BSA Conjugate ML

Frozen Solution, 1 mg conjugate per tube ≥99% conjugates by SEC HPLC

Product Number: CM52135



Product Description

Ciprofloxacin, commonly referred to as Cipro or CIP, is a fluoroquinolone type antibiotic. Today, ciprofloxacin is often prescribed as a last resort for infections with antibiotic resistance or mixed infections. Ciprofloxacin works by inhibiting enzymes that are necessary for bacterial DNA replication. Research has also shown that ciprofloxacin may have some anti-

proliferative/apoptotic effects in certain forms of cancer. This ciprofloxacin–BSA conjugate is a medium loading (ML) conjugate with an average of 5 to 10 ciprofloxacin molecules per BSA and can be used for immunization or immunoassay development. Ciprofloxacin is conjugated to BSA via its surface amines. The final conjugate is supplied as a frozen solution in phosphate buffered saline (PBS) and ready to use after defrosting.

The product is sold as either 1 vial of 1 mg (Cat# CM52135-1MG) or 5 vials of 1 mg (Cat# CM52135-5MG). For bulk orders, please contact us for a quote.

Application

- Assay development for detection of ciprofloxacin contaminants.
- Antibody discovery via immunization and hapten recognition.
- Indirect and competitive ELISA assay.

Key Features

- Frozen solution in PBS buffer ready to use.
- Medium loading conjugate with an average 5 to 10 ciprofloxacin molecules per BSA.
- Concentration accurately determined by UV/HPLC analysis.

Storage/Stability

- Recommended storage of the product is below -20°C.
- Expiration before defrosting is 1 year after receiving.
- Once defrosted, maintain at 2-8°C.
- For best quality, use within 1 week of defrosting.

Selected References

- Mihoko K. *et. al.* Development of enrofloxacin ELISA using a monoclonal antibody tolerating an organic solvent with broad cross-reactivity to other new quinolones, *Food and Agricultural Immunology*, **2007**, 18:3-4, 179-187, DOI: 10.1080/09540100701763365
- Li, Y. *et. al.* Production of new class-specific polyclonal antibody for determination of fluoroquinolones antibiotics by indirect competitive ELISA, *Food and Agricultural Immunology*, **2008**, 19:4,251-264, DOI: 10.1080/09540100802471538

• Sharma, P. C. *et. al.* Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects, *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2010**, 25:4, 577-589, DOI: 10.3109/14756360903373350